IP Library Granted Patent US 10,870,854
Granted Patent B2
US 10,870,854 · App. 16/308,669 · Granted Dec 22, 2020

Inhibitory RNA-based therapeutics targeting ANLN for cancer treatment

Inventors: Hao Zhu (Dallas, TX); Shuyuan Zhang (Dallas, TX)
Assignee: The Board of Regents of the University of Texas System
C12N15/113A61K9/127A61K9/51A61K31/7088A61K45/06A61N5/1077A61P35/00C12N2310/14C12N2310/351C12N2310/531C12N2320/31C12N2330/51
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,870,854
App. No.
16/308,669
Granted
Dec 22, 2020
Kind
B2
Abstract

Embodiments of the present disclosure include compositions and methods related to certain siRNA compositions for the treatment of cancer. In specific embodiments, siRNAs are employed for treatment of cancer, including at least liver cancer. Therapeutic methods, compositions, and kits are encompassed in the disclosure.

Claims (14)

1. A method of treating a liver cancer in a subject comprising administering to the subject an effective amount of an interfering RNA or vector encoding the interfering RNA, where the interfering RNA targets an anillin actin binding protein mRNA.

2. The method of claim 1 , wherein the interfering RNA or vector is delivered by liposome or nanoparticle.

3. The method of claim 1 , wherein said interfering RNA or vector is administered systemically or regional to said liver cancer.

4. The method of claim 1 , wherein said interfering RNA or vector is administered intravenously, intratumorally, intrahepatically, intra-arterially, subcutaneously, topically or orally.

5. The method of claim 1 , wherein the method further comprises administering an additional anti-cancer therapy to the individual.

6. The method of claim 5 , wherein the additional anti-cancer therapy comprises surgery, radiation, chemotherapy, hormone therapy, immunotherapy, or a combination thereof.

7. The method of claim 6 , wherein the radiation comprises external beam radiation therapy.

8. The method of claim 1 , wherein said administering is repeated.

9. The method of claim 1 , wherein said liver cancer is recurrent or drug resistant.

10. The method of claim 1 , wherein said interfering RNA is about 21-23 bases in length.

11. The method of claim 1 , comprising a sequence at least 80%, 85%, 90% or 95% identical to SEQ ID NO: 1.

12. The method of claim 1 , comprising the sequence of SEQ ID NO: 1.

13. The method of claim 1 , consisting of the sequence of SEQ ID NO: 1.

14. The method of claim 1 , wherein the liver cancer is metastatic from a liver cancer or metastatic to the liver.

Assignments (2)
CONFIRMATORY LICENSE Recorded Mar 9, 2020
From: UT SOUTHWESTERN MEDICAL CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 052121/0424 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2019
From: ZHU, HAO; ZHANG, SHUYUAN
To: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 047946/0896 →
Continuity (2)
Provisional Application 62347803 · Jun 9, 2016
Related Publication 20190153448A1 · May 23, 2019